CVM:NYSEAMERICAN
CEL-SCI Corp
$1.66
arrow_upward
+11.41%(+0.17) 1D
$1.65
arrow_downward
-0.60% (-0.0100)bedtimeAfter hours
Closed: Sep 18, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CVM...
Open
$1.53
High
$1.70
Low
$1.51
Mkt. cap
29.20M
Avg. vol.
142.51K
Volume
270.34K
52-wk high
$10.83
52-wk low
$0.89
EPS
-$2.68
Beta
0.61
Shares outstanding
17.59M
No. of employees
43
Open
$1.53
High
$1.70
Low
$1.51
Mkt. cap
29.20M
Avg. vol.
142.51K
Volume
270.34K
52-wk high
$10.83
52-wk low
$0.89
EPS
-$2.68
Beta
0.61
Shares outstanding
17.59M
No. of employees
43
News stories
From web sources and news partners
CarePlus VietNam
·
1 month ago
Cel-Sci Corporation (CVM) Nears Support as Shares Dip 1.57% in Range-Bound Trading - Chart Pattern Alerts
Profile
Cel-Sci Corporation, is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products.
Cel-Sci's main product is the drug Multikine, an immunotherapeutic agent designed to fight cancer by stimulating the body's immune system. Multikine is currently in Phase III of Clinical Trials with the Food and Drug Administration. Multikine has also been referred to as Leukocyte Interleukin Injection. Multikine was in Phase II testing of patients with head and neck cancer in the early 2000s, in which it demonstrated tumor-reducing ability. In January 2007, the US cleared the Phase 3 trial and Multikine was designated as an orphan drug by the FDA for neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck. A total of 928 patients were enrolled in the head and neck cancer drug trial at that time. Subsequently, in June 2021, the company announced that the study missed its primary endpoint. Wikipedia
About CEL-SCI Corp
CEO-
Employees43
FoundedMar 1983
HeadquartersVienna, Virginia, United States
SectorBiotechnology
Websitecel-sci.com